Zevra Therapeutics (ZVRA) Invested Capital: 2014-2025
Historic Invested Capital for Zevra Therapeutics (ZVRA) over the last 10 years, with Sep 2025 value amounting to $194.5 million.
- Zevra Therapeutics' Invested Capital rose 178.74% to $194.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $194.5 million, marking a year-over-year increase of 178.74%. This contributed to the annual value of $99.2 million for FY2024, which is 0.40% down from last year.
- Zevra Therapeutics' Invested Capital amounted to $194.5 million in Q3 2025, which was up 9.30% from $177.9 million recorded in Q2 2025.
- Over the past 5 years, Zevra Therapeutics' Invested Capital peaked at $439.6 million during Q2 2023, and registered a low of $32.5 million during Q2 2024.
- Its 3-year average for Invested Capital is $154.7 million, with a median of $99.2 million in 2024.
- In the last 5 years, Zevra Therapeutics' Invested Capital slumped by 92.61% in 2024 and then soared by 447.82% in 2025.
- Quarterly analysis of 5 years shows Zevra Therapeutics' Invested Capital stood at $127.1 million in 2021, then slumped by 40.91% to $75.1 million in 2022, then skyrocketed by 32.54% to $99.6 million in 2023, then dropped by 0.40% to $99.2 million in 2024, then surged by 178.74% to $194.5 million in 2025.
- Its Invested Capital was $194.5 million in Q3 2025, compared to $177.9 million in Q2 2025 and $41.0 million in Q1 2025.